InvestorsHub Logo
Followers 116
Posts 1882
Boards Moderated 0
Alias Born 11/22/2017

Re: A deleted message

Sunday, 08/18/2019 6:08:44 PM

Sunday, August 18, 2019 6:08:44 PM

Post# of 709746

Guys, if you don't know the 4th RA and spending time figuring it out. You are being left in a complete darkness. This is not a company secret, it cant be. I understand that they may need to hide some information. But not this.

SEC has to investigate this FRAUD!!!!



PHYInvestor,
Please read these Press Releases from Northwest Biotherapeutics:

Aug 11, 2014

The Company has obtained approval from the US FDA and the UK Medicines and Healthcare Products Regulatory Agency (MHRA) and conditional approval from the German regulatory authority (the Paul Ehrlich Institute, or PEI). The Company is now working toward the final approval from the PEI.
https://nwbio.com/nw-bio-obtains-approvals-for-enhancements-of-phase-iii-trial-of-dcvax-l-for-gbm-brain-cancer/



BETHESDA, MD, February 19, 2015 – Northwest Biotherapeutics (NASDAQ: NWBO) (“NW Bio”), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that the Company’s ongoing Phase III clinical trial of DCVax-L for Glioblastoma multiforme (GBM) brain cancer has been approved by Health Canada (the Canadian regulatory authority) to proceed in Canada, has completed the approval processes at two sites, and is under way screening patients for enrollment.
https://nwbio.com/nw-bios-phase-iii-trial-dcvax-l-gbm-brain-cancer-approved-proceed-canada-way-two-sites/


Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News